Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: PARP inhibitor

Primary results of rucaparib in ovarian cancer 

Presented By
Prof. Bradley Monk, University of Arizona, AZ, USA
Trial
Phase 3, ATHENA-MONO
Conference
ASCO 2022

5 August, 2022 15:28

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By
Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada
Trial
Phase 3, PROpel
Conference
ASCO GU 2022

8 April, 2022 11:25

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC

Presented By
Dr Kim Chi, University of British Columbia, Canada
Trial
Phase 3, MAGNITUDE
Conference
ASCO GU 2022

8 April, 2022 11:25

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By
Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA
Trial
Phase 2, BAYOU
Conference
ASCO GU 2022

8 April, 2022 11:19

Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma

Presented By
Dr Simon Crabb, University of Southampton, UK
Trial
Phase 2, ATLANTIS
Conference
ASCO GU 2022

8 April, 2022 11:18

Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Presented By
Dr Francesca Vignani, Ordine Mauriziano Hospital, Italy
Trial
Phase 2, Meet-URO12
Conference
ASCO GU 2022

8 April, 2022 11:17

Olaparib is well tolerated as an additional treatment

Presented By
Dr Patricia Ganz, UCLA School of Medicine, CA, USA
Trial
Phase 3, OlympiA
Conference
SABCS 2021

31 January, 2022 22:26

BrighTNess data may change guidelines

Presented By
Prof. Sibylle Loibl, German Breast Group, Germany
Trial
Phase 3, BrighTNess
Conference
ESMO 2021

19 November, 2021 09:49

PARP inhibitor rechallenge improves PFS in ovarian cancer

Presented By
Dr Eric Pujade-Lauraine, Université Paris Descartes, France
Trial
Phase 3, OReO/ENGOT Ov-38
Conference
ESMO 2021

19 November, 2021 09:24

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By
Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA
Trial
Phase 3, NRG-GY004
Conference
ESMO 2021

19 November, 2021 09:20

Interim results of nivolumab + rucaparib in SCLC

Presented By
Dr Aman Chauhan, University of Kentucky, KY, USA
Conference
WCLC 2021

21 September, 2021 13:24

PARP7 inhibitor shows promising results in first-in-human trial

Presented By
Dr Gerald Falchook , Sarah Cannon Research Institute at HealthONE, CO, USA
Trial
Phase 1
Conference
ASCO 2021

12 August, 2021 23:53

Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation

Presented By
Prof. Andrew Tutt , Institute of Cancer Research, UK
Trial
OlympiA
Conference
ASCO 2021

12 August, 2021 22:47

The EFFORT needed to overcome PARP resistance in ovarian cancer

Presented By
Dr. Shannon Neville Westin, University of Texas, MD Anderson Center
Trial
Phase 2, EFFORT
Journal
Physician's Weekly
Conference
ASCO 2021

6 August, 2021 12:40

Adjuvant olaparib extends disease-free survival in BRCA carriers

Presented By
Dr. Judy Ellen Garber, Dana-Farber Cancer Institute, Harvard Medical School
Trial
OlympiA
Journal
Physician's Weekly
Conference
ASCO 2021

6 August, 2021 12:30

New treatment option for patients with mCRPC

Conference
ESMO 2020

25 November, 2020 14:50

Treatment of recurrent ovarian cancer

Conference
ESMO 2020

25 November, 2020 14:35

Ovarian cancer patients benefit from combined maintenance therapy

Presented By
Prof. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France
Trial
Phase 3, PAOLA-1/ENGOT-ov25
Conference
ESMO 2019

26 November, 2019 23:25

Combination of PARP inhibition plus chemotherapy in ovarian cancer

Presented By
Robert Coleman, University of Texas, MD Anderson Cancer Center, Houston, USA
Trial
Phase 3, VELIA
Conference
ESMO 2019

26 November, 2019 22:26

PARP inhibition in selected patients slows progression on advanced prostate cancer

Presented By
Prof. Maha Hussain, Northwestern University, Chicago, USA
Trial
Phase 3, PROfound
Conference
ESMO 2019

26 November, 2019 21:24

PFS benefit with niraparib as first-line maintenance in ovarian cancer

Principal Investigator
Prof. Antonio González Martín, Clinica Universidad de Navarra, Spain
Trial
Phase 3, PRIMA/ENGOT-OV26/GOG-3012
Conference
ESMO 2019

26 November, 2019 14:26
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy